Trials / Completed
CompletedNCT01392742
An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin
Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 443 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate predictors of early on-treatment response and sustained virological response in patients with chronic hepatitis C receiving Pegasys (peginterferon alfa-2a) and ribavirin. Data will be collected from patients on treatment (24 or 48 weeks) and 24 weeks after the end of treatment.
Conditions
Timeline
- Start date
- 2011-05-31
- Primary completion
- 2014-07-31
- Completion
- 2014-07-31
- First posted
- 2011-07-12
- Last updated
- 2017-04-10
- Results posted
- 2015-12-14
Locations
9 sites across 1 country: Bulgaria
Source: ClinicalTrials.gov record NCT01392742. Inclusion in this directory is not an endorsement.